Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Net Cash Flow (2016 - 2025)

Immucell's Net Cash Flow history spans 16 years, with the latest figure at -$79367.0 for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 57.47% year-over-year to -$79367.0; the TTM value through Dec 2025 reached $48599.0, down 98.25%, while the annual FY2025 figure was $48599.0, 98.25% down from the prior year.
  • Net Cash Flow reached -$79367.0 in Q4 2025 per ICCC's latest filing, up from -$2.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $3.9 million in Q2 2021 to a low of -$3.0 million in Q4 2022.
  • Average Net Cash Flow over 5 years is -$157155.3, with a median of -$111327.0 recorded in 2021.
  • Peak YoY movement for Net Cash Flow: crashed 981.81% in 2022, then surged 4672.9% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$310291.0 in 2021, then crashed by 878.5% to -$3.0 million in 2022, then soared by 66.71% to -$1.0 million in 2023, then soared by 95.01% to -$50401.0 in 2024, then crashed by 57.47% to -$79367.0 in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Net Cash Flow are -$79367.0 (Q4 2025), -$2.1 million (Q3 2025), and $1.4 million (Q2 2025).